Skip to main content
WeightCited

DHEA per Abdominal Fat Reduction

C Evidenze Evidenza limitata da studi di piccole dimensioni, ma esistono alcuni segnali positivi.

An 8-week RCT (n=45) found 7-Keto DHEA plus exercise produced greater weight loss (2.88 kg vs. 0.97 kg placebo). Meta-analysis in elderly found modest abdominal fat reduction. Long-term safety is unclear and DHEA is banned by WADA.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Ddhea\u0026condition\u003Dabdominal\u002Dfat'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

In sintesi

An 8-week RCT (n=45) found 7-Keto DHEA plus exercise produced greater weight loss (2.88 kg vs. 0.97 kg placebo). Meta-analysis in elderly found modest abdominal fat reduction. Long-term safety is unclear and DHEA is banned by WADA.

Key Study Findings

Other n=60 7 weeks
Curcumin mitigates polycystic ovary syndrome in mice by suppressing TLR4/MyD88/NF-κB signaling pathway activation and reducing …
Dose: 200 mg/kg for 45 days vs: DHEA-induced PCOS model controls Outcome: PCOS attenuation via TLR4/MyD88/NF-kB pathway Effetto: BW p=0.025, testosterone p=0.005 <0.05 multiple endpoints

Popolazione: DHEA-induced PCOS C57BL/6J mice (4 groups, n=15)

In Vitro 3.0 weeks
Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice.
Dose: 4 g vs: Control Outcome: Gut microbiota composition Effetto: None None

Popolazione: None

Key Statistics

5

Studi

200

Partecipanti

Positive

C

Grado

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
25-50 mg/day DHEA
guidance:
Guided by serum DHEA-S levels
7ketodhea:
100 mg 2x/day

Limite massimo: 50 mg/day for general use; higher doses under medical supervision only

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
200 mg/kg for 45 days 7 weeks Positive 60
4 g 3.0 weeks Positive --

Momento migliore per l'assunzione: Morning (mimics natural diurnal pattern)

Safety & Side Effects

Effetti collaterali segnalati

  • Acne
  • Hair loss
  • Facial hair growth (women)
  • Mood changes
  • Hormonal side effects

Interazioni note

  • Hormone-sensitive cancers (avoid)
  • Antiestrogens (may counteract)
  • Insulin and diabetes medications
  • WADA-banned in competitive sports

Livello di assunzione massimo tollerabile: 50 mg/day for general use; higher doses under medical supervision only

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does DHEA help with Abdominal Fat Reduction?
Based on 5 studies with 200 participants, there is limited but promising evidence that DHEA may support Abdominal Fat Reduction management. Our evidence grade is C (Some Evidence).
How much DHEA should I take for Abdominal Fat Reduction?
Studies have used various dosages. A commonly studied range is 25-50 mg/day DHEA. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of DHEA?
Reported side effects may include Acne, Hair loss, Facial hair growth (women), Mood changes. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for DHEA and Abdominal Fat Reduction?
We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

References

  1. [1] Qin Yang et al.. Sci Rep. 2024. Curcumin mitigates polycystic ovary syndrome in mice by suppressing TLR4/MyD88/NF-κB signaling pathway activation and reducing intestinal mucosal permeability. doi:10.1038/s41598-024-81034-5 PubMed
  2. [2] Jing Xue et al.. Endocr J. 2019. Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. doi:10.1507/endocrj.EJ18-0567 PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.